On January 3, 2025 Rakovina Therapeutics, Inc. (TSX: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel DNA-damage response technologies, reported its participation in events and meetings being held alongside the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco (Press release, Rakovina Therapeutics, JAN 3, 2025, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-to-connect-with-industry-leaders-during-43rd-annual-j-p-morgan-healthcare-conference-week [SID1234649404]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Showcasing Innovation on a Global Stage
As the premier healthcare investment symposium, the J.P. Morgan Healthcare Conference attracts thousands of global leaders, investors, and innovators from the biopharmaceutical and healthcare sectors. Rakovina Therapeutics will leverage this opportunity to highlight its progress in AI-driven drug discovery and the transformative potential of its advancements in cancer treatment.
Rakovina will engage in meetings held outside the main conference with interested parties, including industry leaders, potential collaborators, and members of the investment community. These meetings aim to foster partnerships and explore new opportunities to advance the company’s mission.
"The conference and surrounding engagements serve as valuable platforms to showcase Rakovina Therapeutics’ progress in AI-driven drug discovery and its transformative potential for cancer treatment," said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. "It is an opportunity to engage with industry leaders, partners, and the investment community as we continue to drive innovation in the DNA-damage response space."
2025: Accelerating Progress and Innovation
The upcoming year holds significant promise for Rakovina Therapeutics as it strives to make key advancements in its mission to develop innovative cancer treatments. The company plans to progress its AI-identified drug candidates through preclinical validation, preparing them for entry into clinical trials, marking a crucial step forward. Concurrently, it aims to enhance its AI-driven platforms, streamlining the drug discovery process to accelerate the development of novel therapies.
Strategic partnerships will remain a cornerstone of the company’s strategy, facilitating the swift development and delivery of innovative cancer treatments to patients. These initiatives exemplify Rakovina’s commitment to leveraging cutting-edge technology, fostering collaboration, and transforming the landscape of cancer care.
Stock Option Grant
The Company also announces that its board of directors approved the grant of 4,330,00 stock options ("Options") to certain officers and directors of the Company pursuant to the Company’s Long Term Incentive Plan. The Options are exercisable at $0.185 per share for five years from the grant date and will vest in equal parts every six months over the next three years.